The ethical framing of personalized medicine

Purpose of reviewPersonalized medicine encompasses the use of biological information such as genomics to provide tailored interventions for patients. The review explores the ethical, legal, and social issues that have emerged with personalized medicine and must be considered because of the complex nature of providing individualized care within a clinical setting. Recent findingsRecent studies found that the use of personalized medicine presents challenges in multiple areas: biobanking and informed consent, confidentiality, genetic discrimination, return of results, access to treatment, clinical translation, direct-to-consumer genetic testing, emerging duties, and knowledge mobilization. SummaryAlthough personalized medicine provides benefits in treating patients in a manner that is more suited to their genetic profile, there are challenges that must be discussed to ensure the protection and fair treatment of individuals. The issues concerning personalized medicine are widespread, and range from individual privacy to the stratification and discrimination of sub-populations based on ethnicity. These issues have considerable impact on the individual and society. A thorough exploration of these ethical issues may identify novel challenges as well as potential avenues for resolution.

[1]  A. Moyer,et al.  Changes in Specialists’ Perspectives on Cancer Genetic Testing, Prophylactic Surgery and Insurance Discrimination: Then and Now , 2014, Journal of Genetic Counseling.

[2]  A. Moyer,et al.  Erratum to: Changes in Specialists’ Perspectives on Cancer Genetic Testing, Prophylactic Surgery and Insurance Discrimination: Then and Now , 2014, Journal of Genetic Counseling.

[3]  R. Pyeritz,et al.  "Use it or lose it" as an alternative approach to protect genetic privacy in personalized medicine. , 2014, Urologic oncology.

[4]  E. Juengst,et al.  Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine. , 2014, Urologic oncology.

[5]  W. Rogowski,et al.  What is personalized medicine: sharpening a vague term based on a systematic literature review , 2013, BMC medical ethics.

[6]  Leslie G Biesecker,et al.  Research participants’ attitudes towards the confidentiality of genomic sequence information , 2013, European Journal of Human Genetics.

[7]  M. Rothstein Genetic discrimination in employment is indefensible. , 2013, The Hastings Center report.

[8]  B. Knoppers,et al.  Life insurance: genomic stratification and risk classification , 2013, European Journal of Human Genetics.

[9]  Iftikhar J. Kullo,et al.  Ethical, legal, and social implications of incorporating genomic information into electronic health records , 2013, Genetics in Medicine.

[10]  Pascal Su,et al.  Direct-to-Consumer Genetic Testing: A Comprehensive View , 2013, The Yale journal of biology and medicine.

[11]  D M Roden,et al.  Genomic Medicine, Precision Medicine, Personalized Medicine: What's in a Name? , 2013, Clinical pharmacology and therapeutics.

[12]  J. Roberts,et al.  Direct-to-Consumer Genetic Testing and Personal Genomics Services: A Review of Recent Empirical Studies , 2013, Current Genetic Medicine Reports.

[13]  Wolfgang Kuchinke,et al.  Ethical concerns caused by integrative patient empowerment solutions for personalized medicine , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[14]  Noah Levin A defense of genetic discrimination. , 2013, The Hastings Center report.

[15]  Bartha Maria Knoppers,et al.  Genotype-driven recruitment: a strategy whose time has come? , 2013, BMC Medical Genomics.

[16]  E. Cuppen,et al.  Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Kenneth Cornetta,et al.  Balancing personalized medicine and personalized care. , 2013, Academic medicine : journal of the Association of American Medical Colleges.

[18]  Ellen Wright Clayton,et al.  Managing incidental genomic findings: legal obligations of clinicians , 2013, Genetics in Medicine.

[19]  Yann Joly,et al.  Genetic discrimination and life insurance: a systematic review of the evidence , 2013, BMC Medicine.

[20]  Y. Bombard,et al.  Citizens' perspectives on personalized medicine: a qualitative public deliberation study , 2013, European Journal of Human Genetics.

[21]  Jane S. Paulsen,et al.  Perception, experience, and response to genetic discrimination in Huntington's disease: the Australian results of The International RESPOND-HD study. , 2013, Genetic testing and molecular biomarkers.

[22]  A Cecile J W Janssens,et al.  A tiered-layered-staged model for informed consent in personal genome testing , 2012, European Journal of Human Genetics.

[23]  B. Knoppers,et al.  Personalized medicine and access to health care: potential for inequitable access? , 2012, European Journal of Human Genetics.

[24]  L. Beskow,et al.  IRB chairs' perspectives on genotype-driven research recruitment. , 2012, IRB.

[25]  Zhengjia Chen,et al.  Research biopsies in phase I studies: views and perspectives of participants and investigators. , 2012, IRB.

[26]  G. Ginsburg,et al.  The path to personalized medicine. , 2002, Current opinion in chemical biology.

[27]  B. Knoppers,et al.  Pediatric research 'personalized'? International perspectives on the return of results. , 2013, Personalized medicine.

[28]  klaguia Genetic Information and Insurance Underwriting: Contemporary Issues and Approaches in the Global Economy Insurance , 2008 .